Arixtra 7.5mg Injection
Marketer
Glaxo SmithKline Pharmaceuticals Ltd
Salt Composition
Fondaparinux (7.5mg)
Overview Arixtra 7.5mg Injection
Fondaparinux 7.5mg Injection is an antithrombotic medication employed to manage deep vein thrombosis (leg vein clots) and pulmonary embolism (lung artery clots). Its action prevents the development of harmful blood clots within the circulatory system. This injection also mitigates clot risk in patients following knee or hip replacement procedures, or those experiencing prolonged immobility. Administration requires medical oversight; dosage and treatment length are determined by your physician. Continue all other prescribed medications concurrently. Increased bleeding risk is a potential side effect; report any unusual bleeding (e.g., petechiae, hematuria, melena) immediately. Prior to use, disclose any bleeding disorders, hepatic or renal impairment, pregnancy, breastfeeding, and all other current medications to your doctor.
Primary Ingredients of Arixtra 7.5mg Injection
The provided text is "undefined," therefore no rephrasing is possible.
Uses of Arixtra 7.5mg Injection
Blood clots in deep veins and lungs
Major Benefits of Arixtra 7.5mg Injection:
The medication will be administered by your physician or registered nurse; please do not attempt self-medication.
Common Side effects of Arixtra 7.5mg Injection:
- Bleeding
- Anemia (low number of red blood cells)
How to use Arixtra 7.5mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Arixtra 7.5mg Injection works:
Fondaparinux 7.5mg injection is a blood thinner. It inhibits the activity of factor Xa, a clotting protein, within the bloodstream. This action prevents the development of undesirable blood clots (thrombi) in the circulatory system.
SAFETY ADVICE
AlcoholUNSAFE
Combining Arixtra 7.5mg Injection with alcohol is inadvisable.
PregnancySAFE IF PRESCRIBED
Fondaparinux 7.5mg injection is typically deemed safe for use in pregnancy. Preclinical trials in animals revealed minimal or no negative impacts on fetal development; nevertheless, data from human studies are scarce.
Breast feedingSAFE IF PRESCRIBED
Fondaparinux 7.5mg injection is likely safe for breastfeeding mothers. Available human data indicates minimal risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of a 7.5mg Arixtra injection on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneyCAUTION
Fondaparinux 7.5mg injection requires careful administration in individuals with impaired renal function. Dosage modification for Fondaparinux 7.5mg injection might be necessary. Physician consultation is advised. Fondaparinux 7.5mg injection is contraindicated in patients exhibiting severe kidney disease.
LiverCAUTION
Fondaparinux 7.5mg injection requires careful administration in individuals with significant hepatic impairment. Dosage modification of Fondaparinux 7.5mg injection might be necessary. Physician consultation is advised.
What if you forget to take Arixtra 7.5mg Injection :
Should you forget a dose of Arixtra 7.5mg Injection, administer it promptly. However, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take a double dose.
Facts to Know About Arixtra 7.5mg Injection
| Label | Value |
|---|---|
| Chemical Type | Glucopyranoside analog |
| Developing Habits | No. |
| Type of Therapy | Heart |
| Actions | Activated Factor X-selective inhibitor |
3,018 People bought this recently